EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction

Positive

AI Analysis

Summary

EpiVax announced the release of AI-enhanced updates to its ISPRI proprietary platform for immunogenicity prediction in biotherapeutics, including an updated JanusMatrix model. This is a routine product enhancement announcement with no material clinical or regulatory catalyst.

Importance:3/10

Sentiment:

0.30

AI/MLPlatform TechnologyImmunogenicityIn SilicoProduct Launch

Read the original article

Published by PR Newswire Pharma on September 2, 2026 3:16 PM

Read Original